Exploring enzyme inhibition profiles of novel halogenated chalcone derivatives on some metabolic enzymes: Synthesis, characterization and molecular modeling studies
0301 basic medicine
Alpha-Glycosidase
Design
Acetylcholinesterase Inhibitors
Esterase
Structure-Activity Relationship
03 medical and health sciences
Chalcone
Chalcones
Humans
Anhydrase Isoenzymes I
Carbonic Anhydrase Inhibitors
Carbonic anhydrase
Molecular Structure
Carbonic-Anhydrase
Hca-I
540
3. Good health
Molecular Docking Simulation
Enzyme inhibition
Anticancer
Butyrylcholinesterase
Molecular docking
Acetylcholinesterase
Biological Evaluation
Cholinesterase Inhibitors
DOI:
10.1016/j.compbiolchem.2022.107748
Publication Date:
2022-07-28T16:40:54Z
AUTHORS (8)
ABSTRACT
Enzyme inhibition is a very active area of research in drug design and development. Chalcone derivatives have a broad enzyme inhibitory activity and function as potential molecules in the development of new drugs. In this study, the synthesized novel halogenated chalcones with bromobenzyl and methoxyphenyl moieties were evaluated toward the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes and human erythrocyte carbonic anhydrase I (hCA I), and II (hCA II) isoenzymes. They showed highly potent inhibition ability toward AChE with Ki values of 1.83 ± 0.21-11.19 ± 0.96 nM and BChE with Ki values of 3.35 ± 0.91-26.70 ± 4.26 nM; hCA I with Ki values of 29.41 ± 3.14-57.63 ± 4.95 nM, and hCA II with Ki values of 24.00 ± 5.39-54.74 ± 1.65 nM. Among the tested enzyme inhibitions, compounds 14 and 13 were the most active compounds against AChE and BChE. Docking studies were performed to the most active compounds against AChE, BChE, hCA I and hCA II to propose a binding mode in the active site and molecular dynamics simulations were studied to check the molecular interactions and the stability of the ligands in the active site. The results may contribute to the development of new drugs particularly to treat some global disorders including Alzheimer's disease (AD), glaucoma, and diabetes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (86)
CITATIONS (17)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....